Key inflammatory pathway activations in the MCI stage of Alzheimer’s disease
Abstract
To determine the key inflammatory pathways that are activated in the peripheral and CNS compartments at the mild cognitive impairment (MCI) stage of Alzheimer’s disease (AD).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 01, 2019
- Source ID
- 10.1002/acn3.50827
Entities
People
- Bruce T. Lamb
- For The Alzheimer’s Disease Neuroimaging Initiative*
- Jagan A Pillai
- James B. Leverenz
- James Bena
- Lynn M. Bekris
- Mark R. Chance
- Sean Maxwell
- Stephen M Rao
Organizations
- AbbVie
- Alzheimer's Association
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Case Western Reserve University
- Cleveland Clinic
- Eisai
- Eli Lilly and Company
- GE HealthCare
- Health Research
- Hoffmann-La Roche
- Indiana University
- Innogenetics
- Johnson & Johnson
- Lou Ruvo Center for Brain Health
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Novartis
- Perrigo Company Plc
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of Southern California